Navigation Links
Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Date:10/15/2007

AMSTERDAM, October 15 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that it has acquired the rights to the discovery of a major mechanism of resistance to the frequently-used breast cancer drug Herceptin(R), which is published in the October 15 issue of the journal "Cancer Cell".

The antibody drug Herceptin(R) targets the HER2 protein, which is hyper-active in about one in four breast cancers and the HER2 protein contributes to aggressive cancer behavior. Striking initial responses are observed in combination with chemotherapy in more than half of treated patients. However, the majority of responding patients eventually develop resistance to Herceptin-based therapies. The laboratory of Agendia's Chief Scientific Officer, Prof. Rene Bernards, today published a rapid method to identify biomarkers associated with non-responsiveness to cancer drugs in cell culture and used the technology to identify a mechanism of resistance to Herceptin-based cancer therapy. His work also demonstrated that these biomarkers indeed have predictive value in patients treated with this drug, thus validating the approach.

"The availability of biomarkers that predict responses to cancer therapy is instrumental to the rational use of cancer drugs in the clinic. Elucidating the molecular mechanism of drug resistance can be critical to identify patients that fail to respond to therapy and may help design more efficient treatment protocols", says Rene Bernards. "Although more work is needed to further validate our findings, the method is generally applicable to find mechanisms of drug resistance and should expedite the development of biomarkers that are associated with therapy non-responsiveness".

The technology used relies on the simultaneous inactivation of thousands of genes through a process known as RNA interference in cells that are sensitive to a specific cancer drug. If the inactivation of a specific gene confers resistance to a cancer drug, cells harboring the inactivated gene can continue to grow in the presence of the cancer drug and can be readily identified. In the present study deregulation of the phosphatidylinositol 3-kinase pathway, which is mutated in up to half of all breast cancer tumors, was identified as a major mechanism of unresponsiveness to Herceptin-based therapies.

"We are very excited by these findings and pleased that we have been able to secure the rights", comments Agendia's CEO, Dr. Bernhard Sixt. "It is likely that a similar mechanism contributes to unresponsiveness to other cancer therapeutics that target the EGF receptor in colon and lung cancer". Agendia will develop a microarray-based diagnostic to identify this drug resistance mechanism.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA approval for it's breast cancer test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(*), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(*) CupPrint(R) is based on a license to the TUA database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):